American Century Companies Inc. Acquires 17,460 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

American Century Companies Inc. raised its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 12.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 159,782 shares of the company's stock after purchasing an additional 17,460 shares during the period. American Century Companies Inc. owned 0.84% of USANA Health Sciences worth $7,229,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC acquired a new stake in shares of USANA Health Sciences in the 4th quarter worth approximately $66,000. CWM LLC lifted its stake in shares of USANA Health Sciences by 21.8% in the 1st quarter. CWM LLC now owns 1,543 shares of the company's stock worth $75,000 after acquiring an additional 276 shares during the period. BOKF NA lifted its stake in shares of USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company's stock worth $133,000 after acquiring an additional 2,031 shares during the period. Trexquant Investment LP acquired a new stake in shares of USANA Health Sciences in the 4th quarter worth approximately $266,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of USANA Health Sciences by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company's stock worth $284,000 after acquiring an additional 494 shares during the period. 54.25% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Paul A. Jones sold 6,266 shares of the business's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Gilbert A. Fuller sold 674 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Paul A. Jones sold 6,266 shares of the business's stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The disclosure for this sale can be found here. Insiders have sold 7,940 shares of company stock worth $311,670 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on USNA shares. DA Davidson reduced their price target on shares of USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating for the company in a research note on Thursday, July 25th. StockNews.com downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Wednesday, July 24th.

USANA Health Sciences Trading Down 0.4 %

Shares of NYSE USNA traded down $0.14 during midday trading on Tuesday, reaching $37.94. The company's stock had a trading volume of 50,555 shares, compared to its average volume of 79,599. The company has a 50 day moving average price of $40.57 and a 200 day moving average price of $44.27. USANA Health Sciences, Inc. has a one year low of $36.05 and a one year high of $60.03. The company has a market cap of $722.79 million, a price-to-earnings ratio of 11.82, a price-to-earnings-growth ratio of 1.28 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its earnings results on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing analysts' consensus estimates of $0.65 by ($0.11). USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The business had revenue of $212.87 million during the quarter, compared to the consensus estimate of $218.64 million. During the same quarter in the previous year, the firm earned $0.89 earnings per share. Research analysts anticipate that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.